Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation

Journal of the American Society of Nephrology

Volumn 22, Issue 11, 2011, Pages 2107-2118

  Sharif, Adnan ^a   Shabir, Shazia ^a   Chand, Sourabh ^a   Cockwell, Paul ^a   Ball, Simon ^a   Borrows, Richard ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; FINGOLIMOD; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; SOTRASTAURIN; TACROLIMUS; TASOCITINIB; THYMOCYTE ANTIBODY; TOFACITINIB; UNCLASSIFIED DRUG;

ARTICLE; CALCINEURIN INHIBITOR SPARING REGIMEN; COCHRANE LIBRARY; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DRUG DOSE REGIMEN; EMBASE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; META ANALYSIS (TOPIC); NEW ONSET DIABETES; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 80555134743     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010111160     Document Type: Article

References (73)

1. Borel JF, Kis ZL: The discovery and development of cyclosporine (Sandimmune). Transplant Proc 23: 1867-74, 1991
2. Calne RY, Thiru S, Mcmaster P, Craddock GN, White DJG, Evans DB, Dunn DC, Pentlow BD, Rolles K: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323-1327, 1978 (Pubitemid 9078430)
3. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309: 809-815, 1983
4. Group EMT: Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. The Lancet 2: 986-989, 1983
5. McMaster P, Haynes IG, Michael J, Adu D, Vlassis T, Roger S, Turney J, Stock S, Buckels J, Mackintosh P, Ezzibdeh M: Cyclosporine in cadaveric renal transplantation: A prospective randomized trial. Transplant Proc 15: 2523-2527, 1983 (Pubitemid 14164140)
6. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508, 2009
7. Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 269: 395-400, 1993 (Pubitemid 23018081)
8. Moore J, Ramakrishna S, Tan K, Cockwell P, Eardley K, Little MA, Rylance P, Shivakumar K, Suresh V, Tomlinson K, Ready A, Borrows R: Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation. Transplantation 87: 578-86, 2009
9. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000 (Pubitemid 30238708)
10. Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M: Prospective randomized study of azathioprine vs. cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clin Exp Nephrol 11: 151-155, 2007 (Pubitemid 47012514)
11. Flechner SM, Glyda M, Tai SS, for the ORION trial Investigators: Delayed graft function (DGF) in two sirolimus (SRL)-based regimens compared with tacrolimus (TAC) and mycophenolate mofetil (MMF) in de novo renal allograft recipients. Presented at American Transplant Congress, Boston, 2009
12. Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A: Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 82: 62-68, 2006 (Pubitemid 44296979)
13. Büchler M, Caillard S, Barbier S, Thervet E, Toupance O, Mazouz H, Hurault de Ligny B, Le Meur Y, Thierry A, Villemain F, Heng AE, Moulin B, Morin MP, Noël C, Lebranchu Y: Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 7: 2522-2531, 2007 (Pubitemid 47561618)
14. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, Slakey D, Peddi VR, Fisher RA, Lawendy N, Wang C, Chan G: Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplant 9: 1936-1945, 2009
15. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol JM, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J: A Phase III study of beletacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 10: 547-557, 2010
16. Durrbach A, Rostaing L, Tricot L, Ouali N, Wolf P, Pouteil-Noble C, Kessler M, Viron B, Thervet E: Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 85: 486-490, 2008
17. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357: 2562-2575, 2007 (Pubitemid 350294223)
18. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002 (Pubitemid 35216097)
19. Flechner SM, Gurkan A, Tai SS, Glickman SLS: Incidence of delayed graft function (DGF) in a sirolimus (SRL)-based versus cyclosporine (CsA)-based regimen in de novo renal allograft recipients. Presented at American Transplant Congress, Boston, 2009
20. Gelens MA, Christiaans MH, van Heurn EL, van den Berg-Loonen EP, Peutz-Kootstra CJ, van Hooff JP: High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 82: 1221-1223, 2006 (Pubitemid 44748026)
21. Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042, 1999 (Pubitemid 29200856)
22. Hamdy AF, El-Agroudy AE, Bakr MA, Mostafa A, El-Baz M, El-Shahawy el-M, Ghoneim MA: Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 5: 2531-2538, 2005
23. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6: 514-522, 2006 (Pubitemid 43382137)
24. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, Gaber AO: Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 77: 1228-1235, 2004 (Pubitemid 38580302)
25. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, Estrada- Oros J, Franco-Abaroa R, George-Micelli E, Rios-Martinez L, Mendez- Machado GF: Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center. Transplantation 82: 1533-1536, 2006 (Pubitemid 44967639)
26. Najarian JS, Fryd DS, Strand M, Canafax DM, Ascher NL, Payne WD, Simmons RL, Sutherland DE: A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 201: 142-157, 1985 (Pubitemid 15170079)
27. Novick AC, Hwei HH, Steinmuller D, Streem SB, Cunningham RJ, Steinhilber D, Goormastic M, Buszta C: Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 42: 154-158, 1986 (Pubitemid 16040444)
28. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005 (Pubitemid 41215486)
29. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP: A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546, 2010
30. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N: Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 89: 1511-1517, 2010
31. Ruggenenti P, Perico N, Gotti E, Cravedi P, D'Agati V, Gagliardini E, Abbate M, Gaspari F, Cattaneo D, Noris M, Casiraghi F, Todeschini M, Cugini D, Conti S, Remuzzi G: Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 84: 956-964, 2007 (Pubitemid 350287376)
32. Cyclosporin a as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 2: 57-60, 1982
33. Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P: Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients. Transpl Int 15: 550-555, 2002 (Pubitemid 36061727)
34. Hall BM, Tiller DJ, Hardie I, Mahony J, Mathew T, Thatcher G, Miach P, Thomson N, Sheil AG: Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 318: 1499-1507, 1988
35. Ponticelli C, Tarantino A, Montagnino G, Aroldi A, Banfi G, De Vecchi A, Zubani R, Berardinelli L, Vegeto A: A randomized trial comparing triple-drug and double-drug therapy in renal transplantation. Transplantation 45: 913-918, 1988
36. Rosenthal JT, Hakala TR, Iwatsuki S, Shaw BW, Jr., Starzl TE: Cadaveric renal transplantation under cyclosporine-steroid therapy. Surg Gynecol Obstet 157: 309-315, 1983 (Pubitemid 13006233)
37. Schaefer HM, Kizilisik AT, Feurer I, Nylander WA, Langone AJ, Helderman JH, Shaffer D: Short-term results under three different immunosuppressive regimens at one center. Transplant Proc 38: 3466- 3467, 2006
38. Vincenti F, Tedesco Silva H, Busque S, O'Connell P, Friedewald J, Yoshida A, Cohney S, Weimar W, Cibrik D, Kim YS, Budde K, Kudlacz E, Lawendy N, Lan S, Lamba M, Krishnaswami S, Chan G: Study of CNI-free immunosuppression with the JAK inhibitor CP-690,550 in de novo kidney transplant patients: 6-month interim analysis. Presented at American Transplant Congress, San Diego, 2010
39. Chan K, Goodall D, Galliford J, Charif R, Duncan N, Papalois V, Hakim N, McLean A, Taube D: Randomized controlled trial of alemtuzumab-tacrolimus monotherapy with daclizumab-tacrolimus-mycophenolate mofetil in renal transplantation. Presented at American Transplant Congress, Boston, 2009
40. de Sévaux RG, Gregoor PJ, Hené RJ, Hoitsma AJ, Vos P, Weimar W, Van Gelder T, Hilbrands LB: A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. J Am Soc Nephrol 12: 1750-1757, 2001 (Pubitemid 32674439)
41. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 7: 560-570, 2007 (Pubitemid 46376436)
42. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, Payne WD, Gruessner RW, Dunn DL, Najarian JS, Sutherland DE, Gillingham KJ, Matas AJ: A prospective randomized trial of steroidfree maintenance regimens in kidney transplant recipients-An interim analysis. Am J Transplant 5: 1529-1536, 2005 (Pubitemid 40839448)
43. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 78: 1332-1340, 2004 (Pubitemid 39507973)
44. Russ GR, Campbell S, Chadban S, Eris J, O'Connell P, Pussell B, Walker R; Australian Rapamune-Tacrolimus Study Group: Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc 35: 115S-117S, 2003 (Pubitemid 36547928)
45. Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C: Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 88: 1194-1202, 2009
46. Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J: A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80: 457-465, 2005 (Pubitemid 41209412)
47. Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A: Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 84: 706-714, 2007 (Pubitemid 47480655)
48. Tedesco-Silva H, Pescovitz MD, Cibrik D, Rees MA, Mulgaonkar S, Kahan BD, Gugliuzza KK, Rajagopalan PR, Esmeraldo Rde M, Lord H, Salvadori M, Slade JM; FTY720 Study Group: Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82: 1689-1697, 2006 (Pubitemid 46035653)
49. Andrés A, Budde K, Clavien PA, Becker T, Kessler M, Pisarski P, Fornara P, Burmeister D, Hené RJ, Cassuto-Viguier E; SENIOR Study Team: A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation 88: 1101-1108, 2009
50. Andrés A, Marcén R, Valdés F, Plumed JS, Solà R, Errasti P, Lauzurica R, Pallardó L, Bustamante J, Amenábar JJ, Plaza JJ, Gómez E, Grinyó JM, Rengel M, Puig JM, Sanz A, Asensio C, Andrés I; NI2A Study Group: A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clin Transplant 23: 23-32, 2009
51. Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P: Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Clin Nephrol 67: 164-175, 2007 (Pubitemid 46416377)
52. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M; CRADUS09 Study Group: Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 85: 821-826, 2008 (Pubitemid 351440746)
53. Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD: Fixed- or controlleddose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 9: 1607-1619, 2009
54. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, Pallardo LM, Eris J, Schena FP, Eisenberger U, Rostaing L, Hmissi A, Aradhye S; FTY720 0124 Study Group: FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6: 2912-2921, 2006
55. Vathsala A, Ona ET, Tan SY, Suresh S, Lou HX, Casasola CB, Wong HC, Machin D, Chiang GS, Danguilan RA, Calne R: Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 80: 765-774, 2005 (Pubitemid 41443758)
56. Kasiske BL, Johnson HJ, Goerdt PJ, Heim-Duthoy KL, Rao VK, Dahl DC, Ney AL, Andersen RC, Jacobs DM, Odland MD: A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 30: 639-645, 1997 (Pubitemid 27465357)
57. Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M: A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 75: 844-851, 2003 (Pubitemid 36373458)
58. Kamar N, Garrigue V, Karras A, Mourad G, Lefrançois N, Charpentier B, Legendre C, Rostaing L: Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study. Am J Transplant 6: 1042-1048, 2006 (Pubitemid 44356656)
59. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY: Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 8: 1480-1485, 2008 (Pubitemid 351989498)
60. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK: Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 83: 1509-1512, 2007 (Pubitemid 46934076)
61. Wienand P, Isenberg J, Stippel D, Schroder T, Baldamus C: Cyclosporin A: Early or delayed onset by prophylactic immunosuppression? Nephrol Dial Transplant 8: 366-368, 1993 (Pubitemid 23129907)
62. Noël C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M, Charpentier B, Touchard G, Berthoux F, Merville P, Ouali N, Squifflet JP, Bayle F, Wissing KM, Hazzan M: Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 20: 1385-1392, 2009
63. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75: SS3-24, 2003
64. Webster AC, Lee VW, Chapman JR, Craig JC: Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 81: 1234-1248, 2006
65. Krentz AJ, Wheeler DC: New-onset diabetes after transplantation: A threat to graft and patient survival. Lancet 365: 640-264, 2005
66. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC: Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomized trial data. BMJ 331: 810, 2005
67. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 4: 583-595, 1994
68. Schold J, Kaplan B: The elephant in the room: Failings of current clinical endpoints in kidney transplantation. Am J Transplant 10: 1163- 1166, 2010
69. Roos-van Groningen MC, Scholten EM, Lelieveld PM, Rowshani AT, Baelde HJ, Bajema IM, Florquin S, Bemelman FJ, de Heer E, de Fijter JW, Bruijn JA, Eikmans M: Molecular comparison of calcineurin inhibitor- induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 17: 881-888, 2006
70. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roosvan Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, ten Berge I, Florquin S: No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus- treated renal transplant recipients at one year. J Am Soc Nephrol 17: 305-312, 2006
71. Kaplan B, Schold JD, Meier-Kriesche HU: Long-term graft survival with neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 14: 2980-2984, 2003 (Pubitemid 37305662)
72. Augustine JJ, Poggio ED, Heeger PS, Hricik DE: Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 86: 529-534, 2008
73. Szczech LA, Berlin JA, Feldman HI: The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 128: 817-826, 1998 (Pubitemid 28267714)